InvestorsHub Logo
Followers 2
Posts 333
Boards Moderated 0
Alias Born 07/19/2016

Re: dafreaks post# 15550

Wednesday, 03/15/2017 11:24:42 AM

Wednesday, March 15, 2017 11:24:42 AM

Post# of 108192
Interesting - speculation that there is a fundamental flaw in the science or management team.
Science - There has NEVER been a bad outcome in trial results. The one patient death wasn't due to the vaccine, but rather the patients disease. Multiple constructs, Phase III trial ongoing, and NOW - tada!! - other companies approaching Advaxis asking them to make their vaccine better!!. Nope, not the science.
Management - as stated in prior threads, nothing DOC has done is out of the ordinary, despite what FBG is shouting about. Personally, as someone who has been here since the TM days, I think DOC has done an outstanding job. Nope, imho, not the management.

So then, what do I think it could be. Well - suppose for just a second, that Advaxis technology may be so versatile (cancer, infectious disease) and effective that it's a game changer, a once in a lifetime opportunity that will turn the company into the next Amgen. What then?? 2 years ago we watched this thing go from zero institutional ownership to 80% or so today. Is this, as they say in poker, a tell?? I believe so. Management continues to buy, buy, and then buy some more. Is this a tell? Yeah, most probably. We've gone from a handful of employee's to around 100. Is this a tell? Sure is. You starting to see a trend here?? Just because the sp isn't moving doesn't mean it won't ever move. The PIII is in progress and interim trial results should be out in about a year to 18 months from now. Before then we'll have EU approval submission and possibly a partnership deal. All this and you speculate that something is fundamentally wrong??
Also, don't forget, while other companies are developing treatments that are effective but possibly too toxic to use safely, those treatments are EXPENSIVE. Advaxis vaccines cost nearly nothing to produce, anything they charge will be profit.

Find a way to remind yourself from time to time just exactly what you're invested in - a company on the cutting edge of a treatment that is so versatile and effective other companies are knocking on our door to help them. Read the writing on the wall and be patient.
GLTAL's
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News